People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Biotechnology, Pharmaceuticals, Software / Tech, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alzheon, Inc. | — | Biotechnology | Series D+ | $172.5M | $1.6B | 2014 |
| Sorbent Therapeutics Inc | — | Pharmaceuticals | Series B | $58.6M | $221.0M | 2010 |
| Limerick Biopharma Inc | — | Pharmaceuticals | Series B | $52.8M | $16.3M | 2009 |
| BIND Biosciences Inc | — | Biotechnology | Series B | $51.4M | $345.2M | 2010 |
| Aira Tech Corp. | — | Software / Tech | Series B | $32.2M | $522.6M | 2017 |
| Spinal Surgical Strategies, Inc. | — | Medical Devices | Pre-Seed | $1.4M | $23.4M | 2013 |
| Goldilocks Therapeutics, Inc. | — | Biotechnology | Seed | $1.2M | $54.7M | 2019 |
Scott Minick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Minick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Harris | 1 | 20 |
| Kristina Burow | 1 | 16 |
| Robert S Langer | 1 | 14 |
| Peter Barton Hutt | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Michael O'Donnell | 1 | 11 |
| Chad Waite | 1 | 11 |
| Noubar Afeyan | 1 | 9 |
| James Wright | 1 | 9 |
| Dennis Langer | 1 | 9 |
| Josh Wolfe | 1 | 8 |
| David Collier | 1 | 8 |
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Steve Dow | 1 | 7 |
| Franklin Berger | 1 | 7 |
| Daniel Murray | 1 | 6 |
| Daniel S. Lynch | 1 | 6 |
| Franz Hefti | 1 | 6 |
| Christopher Noel Dunn | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.